Originally Posted by Anonymous
" There are 100 in the oncology division at merck. They only represent Emend and Zolinza. 185 plus 100 is way too many representatives. Good luck to all."
I dont know how much Zolinza and Emend sell a year but Schering Oncology/Virology promote 4 drugs ,Temodar does a billion alone worldwide.I am surprised Merck has some many Oncology reps, i dont believe Zolinza and Emend are big sellers ? But Merck is interested in Bocephprevir which could be out in 1 to 2 years. They may put Virology with Hiv and make a pure Onc sales force. There may be some cuts but 6 drugs and 285 reps is not way to many. On the Schering side this is their most profitable division
The 100 US reps for Merck's "2" products are way too many.
-Emend sold a paltry $264m Globally in 2008 [This is a primary care drug people]
-Zolinza sold a whopping $15m Globally in 2008 [Your only true oncology drug]
The 185 reps for Schering's 4 products are not enough.
-Temodar = $1.002 BILLION
-Pegintron = $914M
-Intron-A = $234M
-Noxafil = $154M
220 Oncology Reps for Temodar, Intron-A (soon to be Peg), Emend, & Zolinza should suffice. Temodar needs added attention with Avastin's off-label push for new pts. I'm sure the nausea experts from Merck can handle that by themselves???
HIV should add #'s to prepare for Vicriviroc & sell dog Pegintron, until blockbuster boceprevir hits in 2011. Merck Hospital can do a much better job with Noxafil.